In a nutshell This study is comparing the effectiveness of R-CHOP chemotherapy with or without enzastaurin (Kinenza) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL). The main outcome to be measured will be overall survival at the end of the study. The details The current standard first-line treatment for DLBCL is R-CHOP...
Read MoreNon-Hodgkin lymphoma Posts on Medivizor
Can modified chemotherapy treatment improve B-non Hodgkin lymphoma survival rates?
In a nutshell This study examined if a modified chemotherapy treatment can improve outcomes for patients with B-non Hodgkin lymphoma (B-NHL), in lower income countries. This study concluded that reduced-intensity chemotherapy can result in long term survival rates in these patients. Some background B–non-Hodgkin lymphoma (B-NHL) is also known as...
Read MoreLooking for patients with relapsed or unresponsive lymphoma to test a cell therapy
In a nutshell This phase 1 trial is investigating the effectiveness and safety of a new T-cell therapy for relapsed or unresponsive lymphoma. The main outcome to be measured will be the side effects of treatment and long-term survival. This study is being conducted in Chapel Hill, North Carolina, United States. The details In cancer therapy,...
Read MoreSearching for patients with lymphoma to try a new combination treatment
In a nutshell This study will investigate the effects of a new combination of pembrolizumab (Keytruda) and MK-4280 for the treatment of non-Hodgkin lymphoma (NHL). Side effects and response to treatment will be the main effects measured. The details Pembrolizumab and MK-4280 are both targeted therapies for blood cancers. This means that they...
Read MoreBEAM versus BEAC high-dose chemotherapy for patients with non-Hodgkin’s lymphoma
In a nutshell This study evaluated the outcomes of two high-dose chemotherapy regimens for patients with non-Hodgkin’s lymphoma (NHL) before autologous stem cell transplantation (ASCT). This study concluded that the outcomes were similar between both regimens. Some background High-dose chemotherapy is typically used before ASCT to get rid of any...
Read MorePredicting outcomes using the MIPI score for newly-diagnosed patients with MCL
In a nutshell This study evaluated the use of the MIPI score for patients with newly diagnosed mantle cell lymphoma (MCL). This study concluded that the MIPI score may better predict prognosis for these patients. Some background MCL is a type of non-Hodgkin’s lymphoma that significantly differs between individual patients. The MCL international...
Read MoreCombining ibrutinib and umbralisib to treat relapsed/unresponsive mantle cell lymphoma
In a nutshell This study aimed to investigate the safety and effectiveness of ibrutinib (Imbruvica) combined with umbralisib for patients with released/unresponsive mantle cell lymphoma (MCL). This study concluded that the combination of umbralisib and ibrutinib is well tolerated and effective in these patients. Some background Mantle cell...
Read MoreLooking for patients with relapsed or unresponsive mantle cell lymphoma to test a new treatment
In a nutshell This phase 2 trial is evaluating the safety and effectiveness of a new targeted therapy for relapsed or unresponsive mantle cell lymphoma (MCL). The main outcome to be measured is the overall response rate to treatment. The details Ibrutinib (Imbruvica) is a commonly used therapy for patients with relapsed or refractory MCL. This...
Read MoreEvaluating ibrutinib plus nivolumab for relapsed or refractory non-Hodgkin’s lymphoma
In a nutshell This study evaluated the safety and effectiveness of ibrutinib (Imbruvica) plus nivolumab (Opdivo) for relapsed or unresponsive non-Hodgkin’s lymphoma (NHL). This study concluded that this treatment was well-tolerated and showed promising effectiveness in these patients. Some background Treatment remains challenging for high-risk...
Read MoreAre patients with follicular lymphoma more likely to develop congestive heart failure?
In a nutshell This study examined if patients being treated for follicular lymphoma (FL) have an increased risk of developing congestive heart failure (CHF). This study concluded that there is an increased risk of developing CHF in patients diagnosed with FL who received anthracyclines between the ages of 66-75. Some background FL...
Read MoreEvaluating the impact of quality of life at diagnosis on patient outcomes for aggressive lymphoma
In a nutshell This study evaluated whether quality of life (QOL) scores impact outcomes for patients with aggressive lymphoma. This study concluded that QOL scores at diagnosis may predict survival outcomes for these patients. Some background The International Prognostic Index (IPI) is the most widely used tool to predict survival outcomes for...
Read MorePredicting the effects of stem cell transplant in older patients with non-Hodgkin lymphoma.
In a nutshell This study investigated the effects of stem cell transplant for non-Hodgkin lymphoma (NHL) in older patients. The main finding was that patients who responded to chemotherapy had better outcomes after stem cell transplant. Some background Stem cell transplant is often used to treat NHL. This involves the transfer of healthy cells to a...
Read More
